Position of the Transparency Council – Daraprim

At its meeting on 29 July 2024, the Transparency Council adopted position No.  78/2024 on the appropriateness of authorising the reimbursement of Daraprim for the indications congenital toxoplasmosis, ocular toxoplasmosis and central nervous system toxoplasmosis in the course of HIV infection

Publication of the position >>